{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:16Z","timestamp":1777420816784,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-017-3573-1","type":"journal-article","created":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T09:00:36Z","timestamp":1503997236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum"],"prefix":"10.1186","volume":"17","author":[{"given":"Takuma","family":"Ohsuga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-1405","authenticated-orcid":false,"given":"Ken","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Kido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryusuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Abiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Hamanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriomi","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"3573_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9\u201329.","journal-title":"CA Cancer J Clin"},{"key":"3573_CR2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","volume":"23","author":"JD Seidman","year":"2004","unstructured":"Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41\u20134.","journal-title":"Int J Gynecol Pathol"},{"key":"3573_CR3","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1200\/JCO.2008.19.2963","volume":"27","author":"DS Miller","year":"2009","unstructured":"Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, Pearl ML, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the gynecologic oncology group. J Clin Oncol. 2009;27:2686\u201391.","journal-title":"J Clin Oncol"},{"key":"3573_CR4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1158\/1055-9965.EPI-08-0771","volume":"18","author":"MT Goodman","year":"2009","unstructured":"Goodman MT, Shvetsov YB. Incidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995-2004. Cancer Epidemiol Biomark Prev. 2009;18:132\u20139.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"3573_CR5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ygyno.2015.01.534","volume":"136","author":"RD S\u00f8rensen","year":"2015","unstructured":"S\u00f8rensen RD, Schnack TH, Karlsen MA, H\u00f8gdall CK. Serous ovarian, fallopian tube and primary peritoneal cancers: a common disease or separate entities - a systematic review. Gynecol Oncol. 2015;136:571\u201381.","journal-title":"Gynecol Oncol"},{"key":"3573_CR6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609\u201315.","journal-title":"Nature"},{"key":"3573_CR7","first-page":"517","volume":"123","author":"RG Verhaak","year":"2013","unstructured":"Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013;123:517\u201325.","journal-title":"J Clin Invest"},{"key":"3573_CR8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fonc.2015.00229","volume":"5","author":"S Symeonides","year":"2015","unstructured":"Symeonides S, Gourley C. Ovarian cancer molecular stratification and tumor heterogeneity: a necessity and a challenge. Front Oncol. 2015;5:229.","journal-title":"Front Oncol"},{"key":"3573_CR9","doi-asserted-by":"crossref","unstructured":"Konecny GE, Wang C, Hamidi H, Winterhoff B, Kalli KR, Dering J, et al. Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst 2014;106:pii:dju249.","DOI":"10.1093\/jnci\/dju249"},{"key":"3573_CR10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.ajpath.2015.12.029","volume":"186","author":"R Murakami","year":"2016","unstructured":"Murakami R, Matsumura N, Mandai M, Yoshihara K, Tanabe H, Nakai H, et al. Establishment of a novel histopathological classification of high-grade serous ovarian carcinoma correlated with Prognostically distinct gene expression subtypes. Am J Pathol. 2016;186:1103\u201313.","journal-title":"Am J Pathol"},{"key":"3573_CR11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1148\/radiol.14141477","volume":"274","author":"HA Vargas","year":"2015","unstructured":"Vargas HA, Micco M, Hong SI, Goldman DA, Dao F, Weigelt B, et al. Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. Radiology. 2015;274:742\u201351.","journal-title":"Radiology"},{"key":"3573_CR12","doi-asserted-by":"crossref","unstructured":"Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124:1\u20135.","DOI":"10.1016\/j.ijgo.2013.10.001"},{"key":"3573_CR13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3573_CR14","first-page":"367103","volume":"2014","author":"T Feigenberg","year":"2014","unstructured":"Feigenberg T, Clarke B, Virtanen C, Plotkin A, Letarte M, Rosen B, et al. Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int. 2014;2014:367103.","journal-title":"Biomed Res Int"},{"key":"3573_CR15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3802\/jgo.2008.19.4.223","volume":"19","author":"SJ Baek","year":"2008","unstructured":"Baek SJ, Park JY, Kim DY, Kim JH, Kim YM, Kim YT, et al. Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol. 2008;19:223\u20138.","journal-title":"J Gynecol Oncol"},{"key":"3573_CR16","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-08-0196","volume":"14","author":"RW Tothill","year":"2008","unstructured":"Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14:5198\u2013208.","journal-title":"Clin Cancer Res"},{"key":"3573_CR17","doi-asserted-by":"crossref","unstructured":"Murakami R, Matsumura N, Brown JB, Wang Z, Yamaguchi K, Abiko K, Yet al. Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. Gynecol Oncol 2016;141:49\u201356.","DOI":"10.1016\/j.ygyno.2016.02.027"},{"key":"3573_CR18","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1158\/1078-0432.CCR-13-0066","volume":"19","author":"J George","year":"2013","unstructured":"George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, et al. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin Cancer Res. 2013;19:3474\u201384.","journal-title":"Clin Cancer Res"},{"key":"3573_CR19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","volume":"25","author":"RA Soslow","year":"2012","unstructured":"Soslow RA, Han G, Park KJ, Garg K, Olvera N, Spriggs DR, et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol. 2012;25:625\u201336.","journal-title":"Mod Pathol"},{"key":"3573_CR20","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852\u201361.","journal-title":"Lancet Oncol"},{"key":"3573_CR21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1447-0756.2006.00359.x","volume":"32","author":"SJ Lee","year":"2006","unstructured":"Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res. 2006;32:99\u2013106.","journal-title":"J Obstet Gynaecol Res"},{"key":"3573_CR22","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","volume":"34","author":"AA Wright","year":"2016","unstructured":"Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of clinical oncology clinical practice guideline. J Clin Oncol. 2016;34:3460\u201373.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-017-3573-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,29]],"date-time":"2017-08-29T09:00:50Z","timestamp":1503997250000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-017-3573-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3573"],"URL":"https:\/\/doi.org\/10.1186\/s12885-017-3573-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,29]]},"article-number":"580"}}